Zobrazeno 1 - 10
of 379
pro vyhledávání: ''
Autor:
Massimo Dominici, Cinzia Baldessari, Giuseppe Pugliese, Stefano Greco, Fabio Canino, Roberta Depenni
Publikováno v:
Tumori Journal. 107:NP123-NP126
Immune-related myasthenia gravis is a rare, disabling, and potentially fatal adverse event of immune checkpoint inhibitor treatment. It is important to identify and manage it promptly. We present two cases of immune-related de novo myasthenia gravis
Autor:
Barbara Alicja Jereczek-Fossa, Giulia Marvaso, Massimo Sarra Fiore, Luca Bergamaschi, Fabrizio Mastrilli, Daniela Alterio, Giulia Corrao, Gabriella Pravettoni, Mattia Zaffaroni, Roberta Lazzari, Giammaria Bufi, Roberto Orecchia, Maria Cristina Leonardi, Federica Cattani
Publikováno v:
Tumori
Objective: During 2020, medical clinical activities were dramatically modified by the coronavirus disease 2019 (COVID-19) emergency. We aim to evaluate the impact of COVID-19 on radiotherapy (RT) practice in a hub cancer center. Methods: Retrospectiv
Autor:
Akihito Kubo, Masaya Fukami, Toshio Kato, Mika Sato, Hiroyuki Tanaka, Wataru Ohashi, Satoru Ito, Toshiyuki Yonezawa, Yasutaka Kato, Etsuro Yamaguchi, Kenshi Kosaka, Shigehisa Kajikawa
Publikováno v:
Tumori Journal. 107:385-391
Introduction: Increased serum procalcitonin (PCT), a well-known biomarker for sepsis, has been reported in several cancer types. We aimed to investigate the prognostic impact of PCT in non-small cell lung cancer (NSCLC). Methods: Medical records of 5
Autor:
Francesca Corti, Giovanni Fucà, Filippo Pagani, Alessandra Raimondi, Rosalba Miceli, Filippo de Braud, Giovanni Randon, Paolo Manca, Chiara Cremolini, Michele Prisciandaro, Filippo Pietrantonio
Publikováno v:
Tumori Journal. 107:353-359
Background: The RECOURSE trial (Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies) demonstrated an overall survival (OS) benefit of trifluridine/tipiracil (FTD/TPI) vs placebo in refractory metastati
Autor:
Lucia Bisceglia, Margherita Tanzarella, Vincenzo Coviello, Enrico Caputo, Anna Melcarne, Emma Cozzi, Fernando Palma, Francesco Cuccaro, Ivan Rashid, Maria Giovanna Burgio Lo Monaco
Publikováno v:
Tumori Journal. 107:39-45
Introduction:This study presents the incidence of gastrointestinal stromal tumors (GISTs) in an Italian region of over 4 million inhabitants monitored for 10 years and is the largest incidence study of this type of cancer conducted so far in Italy.Me
Autor:
Nathalie Ausias, Patrice Vanelle, Fabrice Barlesi, Roch Giorgi, Marc Montana, Mathieu Peretti, Marie Eve Garcia, François Cavaille
Publikováno v:
Tumori
Tumori, 2021, 107 (1), pp.32-38. ⟨10.1177/0300891620926244⟩
Tumori, Casa Editrice Ambrosiana, 2020, pp.030089162092624. ⟨10.1177/0300891620926244⟩
Tumori, 2021, 107 (1), pp.32-38. ⟨10.1177/0300891620926244⟩
Tumori, Casa Editrice Ambrosiana, 2020, pp.030089162092624. ⟨10.1177/0300891620926244⟩
Background: Pembrolizumab, a humanized immunoglobulin monoclonal antibody directed against the programmed cell death 1 receptor, demonstrated robust efficacy and a manageable safety profile across multiple tumor types in clinical trials. Aim: To inve
Autor:
Hakan Gurkan, Sinem Yalcintepe, Damla Eker, Hilmi Tozkir, Irfan Cicin, Emine Ikbal Atli, Huseyin Ahmet Tezel, Engin Atli, Selma Demir
Publikováno v:
Tumori Journal. 106:510-517
Background: Recent advances in next-generation sequencing (NGS) technology have enabled multigene testing and changed the diagnostic approach to hereditary gastrointestinal cancer/polyposis syndromes. The aim of this study was to analyze different ca
Autor:
Giovanni Randon, Marco Maccauro, Melanie Claps, Filippo Pagani, Giulia Apollonio, Giorgia Peverelli, Giuseppe Procopio, Gianluca Aliberti, Alessandra Raimondi, Ettore Seregni, Pierangela Sepe, Elena Verzoni
Publikováno v:
Tumori Journal. 106:406-412
Introduction: Therapeutic decision-making in metastatic castration-resistant prostate cancer (mCRPC) represents an open challenge. Radium-223 is approved for patients with symptomatic bone metastases, no visceral involvement, progressing after at lea
Autor:
Claudio Zamagni, A. Marino, Gianfranco Filippelli, Claudio Scavelli, Caterina Fontanella, Antonio Febbraro, Anna Maria Quaranta, Pasqualinda Ferrara, Paola Schiavone, Laura Orlando, Palma Fedele, Eufemia Stefania Lutrino, Guido Giordano, Gianluca Dima, Chiara Caliolo, Nicola Calvani, Saverio Cinieri, Mariangela Giampaglia, Daniela Rubino, Domenico Bilancia
Publikováno v:
Tumori
Background: Chemotherapy plus targeted therapy is the established treatment for human epidermal growth factor receptor 2 (HER2)–overexpressing breast cancer (BC). Limited data regarding the safety and activity of the combination of eribulin and tra
Autor:
Erdoğan Çetinkaya, Esin Yentürk, Sevim Purisa, Celalettin Ibrahim Kocaturk, Tevfik Fikret Çermik, Zehra Dilek Kanmaz, Esin Tuncay, Gülfidan Aras, Buge Oz
Publikováno v:
Tumori Journal. 105:501-508
Purpose: Rapid diagnosis of genetic mutations is important for targeted therapies such as EGFR tyrosine kinase inhibitors. KRAS mutation and ALK rearrangement are also important in determining treatment. The purpose of our study was to evaluate the d